Search

Your search keyword '"Mehta‐Shah, Neha"' showing total 527 results

Search Constraints

Start Over You searched for: Author "Mehta‐Shah, Neha" Remove constraint Author: "Mehta‐Shah, Neha"
527 results on '"Mehta‐Shah, Neha"'

Search Results

1. Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial

2. Author Correction: Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial

3. Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study

4. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma

5. The Post-transplant Lymphoproliferative Disorders—Metagenomic Shotgun Microbial Sequencing (PTLD-MSMS) Study Methods and Protocol

6. ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome

7. Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma

8. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas

12. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

14. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303

16. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

18. Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey

21. Hematological Oncology journal women in lymphoma special issue: Latest updates in nodal peripheral T‐cell lymphoma.

22. CAR-modified memory-like NK cells exhibit potent responses to NK-resistant lymphomas

23. T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma

24. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma

25. Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma

30. Phase I Study of Duvelisib Study for Cytokine Release Syndrome Prophylaxis in Patients Receiving Chimeric Antigen Receptor T Cell Treatment for Non-Hodgkin Lymphoma

34. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

37. ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study

42. Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

43. Supplementary Figure 5 from Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma

44. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma

46. A phase II study of interrupted and continuous dose lenalidomide in relapsed/refractory Hodgkin lymphoma

47. Lacutamab in patients with mycosis fungoides: efficacy results according to updated lymph node classification in the TELLOMAK study

49. TCL-054 A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-Cell Lymphoma: Impact of Autologous Stem Cell Transplant (ASCT)

Catalog

Books, media, physical & digital resources